期刊
NATURE REVIEWS IMMUNOLOGY
卷 9, 期 10, 页码 704-716出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2635
关键词
-
类别
资金
- US National Institutes of Health (NIH) [5R01CA105216, 1R01CA120409, 5P01CA066726, 1U19AI082628]
- US NIH [2R01HL56067, R01AI34495, R01CA72669, P01CA142106, P01AI056299, P30AI045008, R01AI057838, R01CA113783, R41CA130547, U19AI066290, U19AI082628, P01AI080192]
- Leukemia and Lymphoma Translational Research
- JDRF Center on Cord Blood Therapies for Type 1 Diabetes
- NATIONAL CANCER INSTITUTE [P01CA065493, P01CA142106, R01CA113783, R01CA072669, R41CA130547, R01CA105216, R01CA120409, P01CA066726] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056067] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI045008, U19AI066290, U19AI082628, R01AI057838, P01AI080192, R01AI034495, P01AI056299] Funding Source: NIH RePORTER
Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
